
Govind Bhagat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/598187/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. Journal of Clinical Investigation, 2003, 112, 1809-1820.	8.2	1,957
2	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
3	Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature, 2009, 459, 717-721.	27.8	969
4	Analysis of the coding genome of diffuse large B-cell lymphoma. Nature Genetics, 2011, 43, 830-837.	21.4	871
5	Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Medicine, 2007, 13, 1203-1210.	30.7	804
6	The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia. Cancer Cell, 2010, 17, 28-40.	16.8	753
7	Coordinated Induction by IL15 of a TCR-Independent NKG2D Signaling Pathway Converts CTL into Lymphokine-Activated Killer Cells in Celiac Disease. Immunity, 2004, 21, 357-366.	14.3	723
8	Overexpression of Interleukin- 1^{12} Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-Derived Suppressor Cells in Mice. Cancer Cell, 2008, 14, 408-419.	16.8	722
9	Nomenclature of the finer branches of the biliary tree: Canals, ductules, and ductular reactions in human livers. Hepatology, 2004, 39, 1739-1745.	7.3	644
10	Akt-Mediated Regulation of Autophagy and Tumorigenesis Through Beclin 1 Phosphorylation. Science, 2012, 338, 956-959.	12.6	630
11	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4021-4031.	1.4	596
12	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nature Genetics, 2014, 46, 166-170.	21.4	534
13	Genetics of Follicular Lymphoma Transformation. Cell Reports, 2014, 6, 130-140.	6.4	471
14	Disruption of the beclin 1–BCL2 autophagy regulatory complex promotes longevity in mice. Nature, 2018, 558, 136-140.	27.8	466
15	Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature, 2014, 506, 240-244.	27.8	455
16	EGFR-Mediated Beclin 1 Phosphorylation in Autophagy Suppression, Tumor Progression, and Tumor Chemoresistance. Cell, 2013, 154, 1269-1284.	28.9	448
17	Bile Acid and Inflammation Activate Gastric Cardia Stem Cells in a Mouse Model of Barrett-Like Metaplasia. Cancer Cell, 2012, 21, 36-51.	16.8	395
18	Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma. Cancer Cell, 2011, 20, 728-740.	16.8	385

#	Article	IF	CITATIONS
19	Risk of malignancy in patients with celiac disease. American Journal of Medicine, 2003, 115, 191-195.	1.5	359
20	Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature, 2012, 488, 652-655.	27.8	343
21	AID is required for germinal center–derived lymphomagenesis. Nature Genetics, 2008, 40, 108-112.	21.4	340
22	Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. Journal of Clinical Oncology, 2014, 32, 114-120.	1.6	338
23	A Signaling Pathway Mediating Downregulation of BCL6 in Germinal Center B Cells Is Blocked by BCL6 Gene Alterations in B Cell Lymphoma. Cancer Cell, 2007, 12, 280-292.	16.8	317
24	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 3986-3996.	1.4	301
25	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 2012, 26, 2103-2113.	7.2	301
26	microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. Journal of Experimental Medicine, 2010, 207, 475-489.	8.5	284
27	Whole-genome sequencing identifies recurrent somatic <i>NOTCH2</i> mutations in splenic marginal zone lymphoma. Journal of Experimental Medicine, 2012, 209, 1553-1565.	8.5	274
28	Reprogramming of CTLs into natural killer–like cells in celiac disease. Journal of Experimental Medicine, 2006, 203, 1343-1355.	8.5	265
29	BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell Lymphoma. Cancer Cell, 2010, 18, 568-579.	16.8	256
30	The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood, 2009, 113, 4918-4921.	1.4	232
31	EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointestinal Endoscopy, 2005, 62, 16-23.	1.0	223
32	A long noncoding RNA associated with susceptibility to celiac disease. Science, 2016, 352, 91-95.	12.6	211
33	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood, 2013, 122, 2673-2682.	1.4	208
34	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2013, 121, 2715-2724.	1.4	206
35	Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. Journal of Clinical Investigation, 2010, 120, 3280-3295.	8.2	206
36	Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nature Medicine, 2011, 17, 87-95.	30.7	193

#	Article	IF	CITATIONS
37	Anemia in celiac disease is multifactorial in etiology. American Journal of Hematology, 2007, 82, 996-1000.	4.1	188
38	Dendritic Cell (DC)-Specific Targeting Reveals Stat3 as a Negative Regulator of DC Function. Journal of Immunology, 2010, 184, 2638-2645.	0.8	187
39	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood, 2011, 117, 1595-1604.	1.4	173
40	Villous Atrophy and Negative Celiac Serology: A Diagnostic and Therapeutic Dilemma. American Journal of Gastroenterology, 2013, 108, 647-653.	0.4	173
41	BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proceedings of the United States of America, 2009, 106, 11294-11299.	7.1	170
42	IRF-4-Binding Protein Inhibits Interleukin-17 and Interleukin-21 Production by Controlling the Activity of IRF-4 Transcription Factor. Immunity, 2008, 29, 899-911.	14.3	168
43	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood, 2016, 127, 3026-3034.	1.4	168
44	Small intestinal CD8+TCRγδ+NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. Journal of Clinical Investigation, 2008, 118, 281-293.	8.2	166
45	RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. Cancer Cell, 2018, 33, 259-273.e7.	16.8	154
46	Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy, 2007, 39, 1086-1091.	1.8	149
47	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica, 2013, 98, 255-263.	3.5	142
48	HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood, 2011, 118, 5506-5516.	1.4	131
49	Prospective study of the role of duodenal bulb biopsies in the diagnosis of celiac disease. Gastrointestinal Endoscopy, 2010, 72, 758-765.	1.0	123
50	The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood, 2008, 112, 2906-2916.	1.4	119
51	An Association Between Microscopic Colitis and Celiac Disease. Clinical Gastroenterology and Hepatology, 2009, 7, 1210-1216.	4.4	117
52	Prevalence and Clinical Implications of Epstein–Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. Clinical Cancer Research, 2014, 20, 2338-2349.	7.0	117
53	Celiac Disease in Normalâ€weight and Overweight Children. Journal of Pediatric Gastroenterology and Nutrition, 2011, 53, 528-531.	1.8	114
54	The whole-genome landscape of Burkitt lymphoma subtypes. Blood, 2019, 134, 1598-1607.	1.4	113

#	Article	IF	CITATIONS
55	Serum cytokine elevations in celiac disease: Association with disease presentation. Human Immunology, 2010, 71, 50-57.	2.4	112
56	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2014, 27, 958-971.	5.5	112
57	Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood, 2014, 124, 2834-2846.	1.4	112
58	Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Human Pathology, 2016, 50, 127-134.	2.0	112
59	Usefulness of CDX2 and TTF-1 in Differentiating Gastrointestinal From Pulmonary Carcinoids. American Journal of Clinical Pathology, 2005, 123, 394-404.	0.7	111
60	Variability in small bowel histopathology reporting between different pathology practice settings: impact on the diagnosis of coeliac disease. Journal of Clinical Pathology, 2012, 65, 242-247.	2.0	109
61	Lack of correlation of degree of villous atrophy with severity of clinical presentation of coeliac disease. Digestive and Liver Disease, 2007, 39, 26-29.	0.9	108
62	<i>TGFBI</i> Deficiency Predisposes Mice to Spontaneous Tumor Development. Cancer Research, 2009, 69, 37-44.	0.9	108
63	Inflammatory Bowel Disease in Patients with Celiac Disease. Inflammatory Bowel Diseases, 2005, 11, 528-532.	1.9	107
64	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunology Research, 2019, 7, 644-657.	3.4	106
65	Duodenal intraepithelial lymphocytosis with normal villous architecture: common occurrence in H. pylori gastritis. Modern Pathology, 2005, 18, 1134-1144.	5.5	104
66	IFN-γ Inhibits Gastric Carcinogenesis by Inducing Epithelial Cell Autophagy and T-Cell Apoptosis. Cancer Research, 2011, 71, 4247-4259.	0.9	104
67	Lineage specification of human dendritic cells is marked by IRF8 expression in hematopoietic stem cells and multipotent progenitors. Nature Immunology, 2017, 18, 877-888.	14.5	101
68	Budesonide in the Treatment of Refractory Celiac Disease. American Journal of Gastroenterology, 2007, 102, 2265-2269.	0.4	100
69	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 764-769.	7.1	100
70	Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood, 2019, 134, 1395-1405.	1.4	100
71	An Update on Celiac Disease Histopathology and the Road Ahead. Archives of Pathology and Laboratory Medicine, 2012, 136, 735-745.	2.5	98
72	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood, 2013, 122, 2683-2693.	1.4	98

#	Article	IF	CITATIONS
73	Bidirectional intragraft alloreactivity drives the repopulation of human intestinal allografts and correlates with clinical outcome. Science Immunology, 2016, 1, .	11.9	98
74	Targeted next generation sequencing of breast implantâ€associated anaplastic large cell lymphoma reveals mutations in <scp>JAK</scp> / <scp>STAT</scp> signalling pathway genes, <i><scp>TP</scp>53</i> and <i><scp>DNMT</scp>3A</i> . British Journal of Haematology, 2018, 180, 741-744.	2.5	98
75	Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood, 2012, 120, 5181-5184.	1.4	96
76	Overexpression of Interleukin-1β in the Murine Pancreas Results in Chronic Pancreatitis. Gastroenterology, 2008, 135, 1277-1287.	1.3	95
77	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. Oncotarget, 2016, 7, 2401-2416.	1.8	93
78	Genetic and phenotypic analysis of B ell postâ€ŧransplant lymphoproliferative disorders provides insights into disease biology. Hematological Oncology, 2008, 26, 199-211.	1.7	89
79	Collagenous sprue is not always associated with dismal outcomes: a clinicopathological study of 19 patients. Modern Pathology, 2010, 23, 12-26.	5.5	89
80	Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood, 2021, 137, 2161-2170.	1.4	88
81	Distinct and Synergistic Contributions of Epithelial Stress and Adaptive Immunity to Functions of Intraepithelial Killer Cells and Active Celiac Disease. Gastroenterology, 2015, 149, 681-691.e10.	1.3	87
82	Progenitor cell expansion: an important source of hepatocyte regeneration in chronic hepatitis. Journal of Hepatology, 2004, 41, 983-991.	3.7	81
83	Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. Clinical Cancer Research, 2015, 21, 4663-4675.	7.0	80
84	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. American Journal of Surgical Pathology, 2018, 42, 293-305.	3.7	80
85	Indolent Small Intestinal CD4+ T-cell Lymphoma Is a Distinct Entity with Unique Biologic and Clinical Features. PLoS ONE, 2013, 8, e68343.	2.5	74
86	FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice. Leukemia, 2016, 30, 1-13.	7.2	72
87	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget, 2015, 6, 5615-5633.	1.8	72
88	Comparison of Commercially Available Serologic Kits for the Detection of Celiac Disease. Journal of Clinical Gastroenterology, 2009, 43, 225-232.	2.2	69
89	Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines. Blood, 2012, 119, 2981-2990.	1.4	69
90	IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis?. Immunological Reviews, 2010, 233, 79-96.	6.0	68

#	Article	IF	CITATIONS
91	Distinguishing patients with celiac disease by quantitative analysis of videocapsule endoscopy images. Computer Methods and Programs in Biomedicine, 2010, 100, 39-48.	4.7	67
92	Prognostic Factors of Hepatosplenic T-cell Lymphoma. American Journal of Surgical Pathology, 2016, 40, 676-688.	3.7	65
93	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia, 2018, 20, 574-593.	5.3	64
94	Dual regulation of IRF4 function in T and B cells is required for the coordination of T–B cell interactions and the prevention of autoimmunity. Journal of Experimental Medicine, 2012, 209, 581-596.	8.5	62
95	Transcription factors of the alternative NF-κB pathway are required for germinal center B-cell development. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9063-9068.	7.1	62
96	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 5597-5614.	1.8	61
97	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2014, 20, 5113-5123.	7.0	60
98	Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Human Pathology, 2007, 38, 315-325.	2.0	59
99	Aggressive presentation of breast implant-associated ALK-1 negative anaplastic large cell lymphoma with bilateral axillary lymph node involvement. Leukemia and Lymphoma, 2009, 50, 831-833.	1.3	59
100	Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14920-14925.	7.1	59
101	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood, 2016, 128, 3083-3100.	1.4	59
102	EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood, 2021, 137, 1468-1477.	1.4	59
103	Indolent T―and NK ell lymphoproliferative disorders of the gastrointestinal tract: a review and update. Hematological Oncology, 2017, 35, 3-16.	1.7	58
104	Hematogones: a review and update. Leukemia and Lymphoma, 2010, 51, 10-19.	1.3	57
105	DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis. Nature, 2020, 579, 291-296.	27.8	57
106	A critical analysis of prognostic factors in North American patients with human Tâ€cell lymphotropic virus typeâ€1â€associated adult Tâ€cell leukemia/lymphoma. Cancer, 2010, 116, 3438-3446.	4.1	56
107	BCL6 as a therapeutic target for lymphoma. Expert Opinion on Therapeutic Targets, 2018, 22, 143-152.	3.4	55
108	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. Haematologica, 2019, 104, e558-e561.	3.5	55

#	Article	IF	CITATIONS
109	Single nucleotide polymorphismâ€arrays provide new insights in the pathogenesis of postâ€transplant diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2010, 149, 569-577.	2.5	53
110	Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus, 2012, 21, 656-661.	1.6	53
111	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood, 2015, 125, 1922-1931.	1.4	53
112	IL10 receptor is a novel therapeutic target in DLBCLs. Leukemia, 2015, 29, 1684-1694.	7.2	53
113	Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus. Oncotarget, 2017, 8, 203-214.	1.8	53
114	Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. The Lancet Gastroenterology and Hepatology, 2019, 4, 960-970.	8.1	52
115	Tissue Transglutaminase Antibodies in Individuals with Celiac Disease Bind to Thyroid Follicles and Extracellular Matrix and May Contribute to Thyroid Dysfunction. Thyroid, 2008, 18, 1171-1178.	4.5	51
116	Role of bone marrow-derived cells in experimental chronic pancreatitis. Gut, 2008, 57, 1113-1120.	12.1	51
117	Increasing incidence of enteropathyâ€associated Tâ€cell lymphoma in the United States, 1973â€2008. Cancer, 2012, 118, 3786-3792.	4.1	51
118	Increased Incidence of Eosinophilic Esophagitis in Children and Adults With Celiac Disease. Journal of Clinical Gastroenterology, 2012, 46, e6-e11.	2.2	50
119	Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas. Modern Pathology, 2019, 32, 216-230.	5.5	50
120	Pathogenesis of Enteropathy-Associated T Cell Lymphoma. Current Hematologic Malignancy Reports, 2018, 13, 308-317.	2.3	49
121	Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood, 2022, 139, 732-747.	1.4	49
122	Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. Clinical Cancer Research, 2015, 21, 2096-2106.	7.0	48
123	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2015, 28, 1555-1573.	5.5	48
124	Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2016, 22, 3593-3605.	7.0	48
125	Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia. Cytometry Part B - Clinical Cytometry, 2007, 72B, 354-362.	1.5	47
126	Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells. Immunity, 2015, 43, 277-288.	14.3	47

#	Article	IF	CITATIONS
127	Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia, 2017, 31, 625-636.	7.2	47
128	Classification of videocapsule endoscopy image patterns: comparative analysis between patients with celiac disease and normal individuals. BioMedical Engineering OnLine, 2010, 9, 44.	2.7	46
129	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 2630-2640.	1.4	46
130	Craniotomy and Survival for Primary Central Nervous System Lymphoma. Neurosurgery, 2019, 84, 935-944.	1.1	46
131	Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract. Haematologica, 2020, 105, 1895-1906.	3.5	46
132	Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget, 2016, 7, 37636-37648.	1.8	46
133	Endoscopic biopsy technique in the diagnosis of celiac disease: OneÂbite or two?. Gastrointestinal Endoscopy, 2015, 81, 1228-1233.	1.0	45
134	FISH analysis in addition to G-band karyotyping: Utility in evaluation of myelodysplastic syndromes?. Leukemia Research, 2010, 34, 420-425.	0.8	44
135	FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease. Blood, 2016, 128, 660-666.	1.4	43
136	Genomic profiles of MALT lymphomas: variability across anatomical sites. Haematologica, 2011, 96, 1064-1066.	3.5	42
137	Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytometry Part B - Clinical Cytometry, 2013, 84B, 21-29.	1.5	42
138	The human thymus perivascular space is a functional niche for viral-specific plasma cells. Science Immunology, 2016, 1, .	11.9	42
139	Distinguishing Between Hepatosplenic T-cell Lymphoma and Î ³ δT-cell Large Granular Lymphocytic Leukemia. American Journal of Surgical Pathology, 2017, 41, 82-93.	3.7	42
140	Tâ€cell postâ€transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. British Journal of Haematology, 2004, 127, 429-432.	2.5	41
141	<scp><i>MYD88</i></scp> somatic mutations in <scp>MALT</scp> lymphomas. British Journal of Haematology, 2012, 158, 662-664.	2.5	41
142	Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4529-4540.	1.4	41
143	Celiac disease diagnosis from videocapsule endoscopy images with residual learning and deep feature extraction. Computer Methods and Programs in Biomedicine, 2020, 187, 105236.	4.7	41
144	Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice. Clinical Cancer Research, 2014, 20, 5240-5254.	7.0	40

#	Article	IF	CITATIONS
145	Clonal T cell receptor gene rearrangements in coeliac disease: implications for diagnosing refractory coeliac disease. Journal of Clinical Pathology, 2018, 71, 825-831.	2.0	40
146	Adult-Onset Nemaline Myopathy and Monoclonal Gammopathy. Archives of Neurology, 2006, 63, 132.	4.5	39
147	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2017, 187, 1700-1716.	3.8	39
148	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Modern Pathology, 2019, 32, 741-754.	5.5	39
149	MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. PLoS ONE, 2014, 9, e114398.	2.5	38
150	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proceedings of the United States of America, 2021, 118, .	7.1	38
151	Celiac Disease in African-Americans. Digestive Diseases and Sciences, 2006, 51, 1012-1015.	2.3	37
152	Deregulated expression of HDAC9 in B-cells promotes development of lymphoproliferative disease and lymphoma. DMM Disease Models and Mechanisms, 2016, 9, 1483-1495.	2.4	37
153	Celiac Disease: Similar Presentations in the Elderly and Young Adults. Digestive Diseases and Sciences, 2010, 55, 3147-3153.	2.3	36
154	Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia, 2018, 32, 353-363.	7.2	36
155	Mature B-cell acute lymphoblastic leukemia with t(9;11) translocation: a distinct subset of B-cell acute lymphoblastic leukemia. Modern Pathology, 2004, 17, 832-839.	5.5	35
156	Hepatitis C–Associated Granulomas After Liver Transplantation. American Journal of Clinical Pathology, 2007, 127, 128-134.	0.7	35
157	Islet Grafting and Imaging in a Bioengineered Intramuscular Space. Transplantation, 2009, 88, 1065-1074.	1.0	35
158	Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 23157-23180.	1.8	35
159	Light chain proximal tubulopathy. Kidney International, 2009, 76, 792-797.	5.2	34
160	Early T-cell precursor leukemia/lymphoma in adults and children. Leukemia Research, 2013, 37, 1027-1034.	0.8	34
161	Prior Endoscopy in Patients with Newly Diagnosed Celiac Disease: A Missed Opportunity?. Digestive Diseases and Sciences, 2013, 58, 1293-1298.	2.3	34
162	Implementation of a polling protocol for predicting celiac disease in videocapsule analysis. World Journal of Gastrointestinal Endoscopy, 2013, 5, 313.	1.2	34

#	Article	IF	CITATIONS
163	Impairment of Mature B Cell Maintenance upon Combined Deletion of the Alternative NF-κB Transcription Factors RELB and NF-κB2 in B Cells. Journal of Immunology, 2016, 196, 2591-2601.	0.8	34
164	Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, E43-E46.	0.4	33
165	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. Oncotarget, 2015, 6, 13933-13945.	1.8	33
166	Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation andc-myc rearrangement terminating in a leukemic phase. American Journal of Hematology, 2007, 82, 59-64.	4.1	32
167	Prevalence and clinical implications of cyclin D1 expression in diffuse large Bâ€cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximabâ€CHOP Consortium Program. Cancer, 2014, 120, 1818-1829.	4.1	32
168	CongenitalMLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) translocations and JH gene rearrangement. Leukemia and Lymphoma, 2005, 46, 1223-1227.	1.3	31
169	Aberrant Tâ€cell antigen expression in B lymphoblastic leukaemia. British Journal of Haematology, 2011, 155, 449-456.	2.5	31
170	Quantitative Assessment of Endoscopic Images for Degree of Villous Atrophy in Celiac Disease. Digestive Diseases and Sciences, 2011, 56, 805-811.	2.3	30
171	Quantitative Estimates of Motility from Videocapsule Endoscopy Are Useful to Discern Celiac Patients from Controls. Digestive Diseases and Sciences, 2012, 57, 2936-2943.	2.3	29
172	Gluten-induced RNA methylation changes regulate intestinal inflammation via allele-specific <i>XPO1</i> translation in epithelial cells. Gut, 2022, 71, 68-76.	12.1	29
173	RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging, 2016, 8, 3321-3340.	3.1	29
174	EBV-associated, extranodal NK-cell lymphoma, nasal type of the breast, after heart transplantation. Modern Pathology, 2004, 17, 125-130.	5.5	28
175	Promoter methylationâ€mediated inactivation of <i>PCDH10</i> in acute lymphoblastic leukemia contributes to chemotherapy resistance. Genes Chromosomes and Cancer, 2011, 50, 1043-1053.	2.8	28
176	The genetic landscape of dural marginal zone lymphomas. Oncotarget, 2016, 7, 43052-43061.	1.8	28
177	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. Journal of Hematology and Oncology, 2020, 13, 148.	17.0	27
178	Recursive partitioning analysis of prognostic factors in postâ€ŧransplant lymphoproliferative disorders (<scp>PTLD</scp>): a 120 case single institution series. British Journal of Haematology, 2015, 171, 491-500.	2.5	26
179	The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. Journal of Neuro-Oncology, 2017, 132, 189-197.	2.9	25
180	Transformation of videocapsule images to detect small bowel mucosal differences in celiac versus control patients. Computer Methods and Programs in Biomedicine, 2012, 108, 28-37.	4.7	24

#	Article	IF	CITATIONS
181	Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. Journal of Clinical Pathology, 2013, 66, 956-961.	2.0	24
182	Survival benefit in patients with peripheral T ell lymphomas after treatments with novel therapies and clinical trials. Hematological Oncology, 2020, 38, 51-58.	1.7	24
183	Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II. American Journal of Surgical Pathology, 2021, 45, 905-916.	3.7	24
184	Incidence of lymphoproliferative disorders in patients with celiac disease. American Journal of Hematology, 2012, 87, 754-759.	4.1	23
185	Differential requirements for the canonical NFâ€₽̂B transcription factors câ€REL and RELA during the generation and activation of mature B cells. Immunology and Cell Biology, 2017, 95, 261-271.	2.3	23
186	Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer. Journal of Molecular Diagnostics, 2018, 20, 822-835.	2.8	23
187	Gastrointestinal T- and NK-cell lymphomas and indolent lymphoproliferative disorders. Seminars in Diagnostic Pathology, 2020, 37, 11-23.	1.5	23
188	Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs. Genome Biology, 2020, 21, 153.	8.8	23
189	Vascular Clips Have No Significant Effect on the Cellular Proliferation, Intimal Changes, or Peak Systolic Velocity at Anastomoses in Rabbit Vein Grafts. Journal of Surgical Research, 2000, 92, 29-35.	1.6	22
190	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
191	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Advances, 2020, 4, 3391-3404.	5.2	22
192	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2022, 28, 972-983.	7.0	22
193	Use of shape-from-shading to estimate three-dimensional architecture in the small intestinal lumen of celiac and control patients. Computer Methods and Programs in Biomedicine, 2013, 111, 676-684.	4.7	21
194	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Modern Pathology, 2015, 28, 1297-1314.	5.5	21
195	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. British Journal of Haematology, 2010, 151, 435-439.	2.5	20
196	Genomic analysis of Nonâ€Splenic Marginal Zone Lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from Memory Bâ€cells. British Journal of Haematology, 2011, 155, 362-365.	2.5	20
197	Robust spectral analysis of videocapsule images acquired from celiac disease patients. BioMedical Engineering OnLine, 2011, 10, 78.	2.7	20
198	Histopathology of Celiac Disease. Gastrointestinal Endoscopy Clinics of North America, 2012, 22, 679-694.	1.4	20

#	Article	IF	CITATIONS
199	Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL). Cell Death and Disease, 2020, 11, 94.	6.3	20
200	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Molecular Cancer Research, 2021, 19, 249-260.	3.4	20
201	Characterizing CD43 expression in haematogones using multicolor flow cytometric analysis. British Journal of Haematology, 2005, 128, 820-823.	2.5	19
202	<i>PCDH10</i> promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosomes and Cancer, 2013, 52, 1030-1041.	2.8	19
203	Atypical Clinical Course in Pediatric Hodgkin Lymphoma. Journal of Pediatric Hematology/Oncology, 2015, 37, 507-508.	0.6	19
204	Sprue-like histology in patients with abdominal pain taking olmesartan compared with other angiotensin receptor blockers. Journal of Clinical Pathology, 2015, 68, 29-32.	2.0	19
205	FYN–TRAF3IP2 induces NF-κB signaling-driven peripheral T-cell lymphoma. Nature Cancer, 2021, 2, 98-113.	13.2	19
206	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging, 2016, 8, 345-365.	3.1	19
207	Hemophagocytic, Non-Secretory Multiple Myeloma. Leukemia and Lymphoma, 2004, 45, 1061-1064.	1.3	18
208	Increased Risk of Papillary Thyroid Cancer in Celiac Disease. Digestive Diseases and Sciences, 2006, 51, 1875-1877.	2.3	18
209	Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling. Haematologica, 2006, 91, 1313-20.	3.5	18
210	Chronic myeloid leukemia and HIV-infection. Leukemia and Lymphoma, 2008, 49, 1155-1160.	1.3	17
211	The Spectrum of B-Cell Non-Hodgkin Lymphomas With Dual <i>IgH</i> - <i>BCL2</i> and <i>BCL6</i> Translocations. American Journal of Clinical Pathology, 2008, 130, 193-201.	0.7	17
212	C-myc protein expression in B-cell acute lymphoblastic leukemia, prognostic significance?. Leukemia Research, 2014, 38, 1061-1066.	0.8	17
213	Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice. Leukemia, 2015, 29, 1414-1424.	7.2	17
214	Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Modern Pathology, 2015, 28, 1202-1213.	5.5	17
215	Endolysosomal trafficking of viral G protein-coupled receptor functions in innate immunity and control of viral oncogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2994-2999.	7.1	17
216	Biopsy Diagnosis of Celiac Disease. Gastroenterology Clinics of North America, 2019, 48, 39-51.	2.2	17

#	Article	IF	CITATIONS
217	Automated interpretation of biopsy images for the detection of celiac disease using a machine learning approach. Computer Methods and Programs in Biomedicine, 2021, 203, 106010.	4.7	17
218	Cytogenetic abnormalities in reactive lymphoid hyperplasia: byproducts of the germinal centre reaction or indicators of lymphoma?. Hematological Oncology, 2011, 29, 81-90.	1.7	16
219	Spectrum of Childhood Epstein-Barr Virus–Associated T-Cell Proliferations and Bone Marrow Findings. Pediatric and Developmental Pathology, 2011, 14, 28-37.	1.0	16
220	Immunohistochemical and T-Cell Receptor Gene Rearrangement Analyses as Predictors of Morbidity and Mortality in Refractory Celiac Disease. Journal of Clinical Gastroenterology, 2013, 47, 593-601.	2.2	16
221	Primary follicular lymphoma of the extrahepatic bile duct mimicking a hilar cholangiocarcinoma: case report and review of the literature. Human Pathology, 2009, 40, 1808-1812.	2.0	15
222	Realâ€ŧime PCRâ€based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia. Hematological Oncology, 2012, 30, 190-193.	1.7	15
223	<i>BCL2</i> mutation spectrum in Bâ€cell nonâ€Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma. Hematological Oncology, 2015, 33, 23-30.	1.7	15
224	Regulation of Effector Treg Cells in Murine Lupus. Arthritis and Rheumatology, 2016, 68, 1454-1466.	5.6	15
225	Quantitative assessment of the degree of villous atrophy in patients with coeliac disease. Journal of Clinical Pathology, 2008, 61, 1089-1093.	2.0	14
226	A Murine Autoimmune Model of Rheumatoid Arthritis and Systemic Lupus Erythematosus Associated with Deregulated Production of IL-17 and IL-21. Methods in Molecular Biology, 2012, 900, 233-251.	0.9	14
227	Innate Lymphoid Cells and Celiac Disease: Current Perspective. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 803-814.	4.5	14
228	Quantitative image analysis of celiac disease. World Journal of Gastroenterology, 2015, 21, 2577.	3.3	14
229	Mitochondrial DNA dysfunction in oncocytic hepatocytes. Liver International, 2003, 23, 397-403.	3.9	13
230	CD117 expression in diffuse large B-cell lymphomas: Fact or fiction?. Pathology International, 2005, 55, 716-723.	1.3	13
231	Intrachromosomal rearrangement of chromosome 3q27: an under recognized mechanism of BCL6 translocation in B-cell non–Hodgkin lymphoma. Human Pathology, 2006, 37, 1093-1099.	2.0	13
232	Fatal CNS vasculopathy in a patient with refractory celiac disease and lymph node cavitation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 209-213.	2.8	13
233	Hematogones are markedly reduced in pediatric acquired aplastic anemia: multiparametric flow cytometric analysis. Leukemia and Lymphoma, 2009, 50, 1951-1957.	1.3	13
234	The pattern of cytoplasmic IgM expression in the context of the three currently recognised maturational stages of hematogones. Leukemia and Lymphoma, 2009, 50, 642-644.	1.3	13

#	Article	IF	CITATIONS
235	Use of basis images for detection and classification of celiac disease. Bio-Medical Materials and Engineering, 2014, 24, 1913-1923.	0.6	13
236	Brentuximab Vedotin (SGN-35) in a 3-Year-Old Child With Relapsed Systemic Anaplastic Large Cell Lymphoma. Journal of Pediatric Hematology/Oncology, 2014, 36, e85-e87.	0.6	13
237	Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. British Journal of Cancer, 2017, 117, 1685-1688.	6.4	13
238	Phenotypic shift of small intestinal intra-epithelial type 1 innate lymphoid cells in celiac disease is associated with enhanced cytotoxic potential. Clinical and Experimental Immunology, 2020, 200, 163-175.	2.6	13
239	Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral TÂcell lymphoma. Cell Reports, 2022, 39, 110695.	6.4	13
240	Do RARA/PML fusion gene deletions confer resistance to ATRA-based therapy in patients with acute promyelocytic leukemia?. Leukemia, 2006, 20, 2193-2195.	7.2	12
241	KHSV ^{â^'} EBV ^{â^'} postâ€ŧransplant effusion lymphoma with plasmablastic features: variant of primary effusion lymphoma?. Hematological Oncology, 2009, 27, 203-210.	1.7	12
242	Langerhans Cell Histiocytosis: Diagnosis on Thyroid Aspirate and Review of the Literature. Head and Neck Pathology, 2015, 9, 496-502.	2.6	12
243	Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. Human Pathology, 2016, 50, 109-117.	2.0	12
244	Automated diagnosis of celiac disease by video capsule endoscopy using DAISY Descriptors. Journal of Medical Systems, 2019, 43, 157.	3.6	12
245	Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large Bâ€cell lymphoma: Current state of the art and unmet clinical needs. British Journal of Clinical Pharmacology, 2021, 87, 284-294.	2.4	12
246	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica, 2022, 107, 201-210.	3.5	12
247	Chronic lymphocytic leukemia and cryoglobulinemic glomerulonephritis. Kidney International, 2007, 71, 93.	5.2	11
248	Aberrant ROCK activation promotes the development of type I diabetes in NOD mice. Cellular Immunology, 2011, 266, 111-115.	3.0	11
249	Absence of <i>NOTCH1</i> gene mutations in MALT lymphomas. British Journal of Haematology, 2012, 157, 382-384.	2.5	11
250	Suggestions for automatic quantitation of endoscopic image analysis to improve detection of small intestinal pathology in celiac disease patients. Computers in Biology and Medicine, 2015, 65, 364-368.	7.0	11
251	Extraction and processing of videocapsule data to detect and measure the presence of villous atrophy in celiac disease patients. Computers in Biology and Medicine, 2016, 78, 97-106.	7.0	11
252	Recommendations to quantify villous atrophy in video capsule endoscopy images of celiac disease patients. World Journal of Gastrointestinal Endoscopy, 2016, 8, 653.	1.2	11

#	Article	IF	CITATIONS
253	Potential carcinogenic effects of cigarette smoke and Swedish moist snuff on pancreas: a study using a transgenic mouse model of chronic pancreatitis. Laboratory Investigation, 2010, 90, 426-435.	3.7	10
254	Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors. Human Pathology, 2010, 41, 1150-1158.	2.0	10
255	Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 71-76.	1.3	10
256	Detection of Nonhematologic Neoplasms by Routine Flow Cytometry Analysis. American Journal of Clinical Pathology, 2020, 153, 99-104.	0.7	10
257	Alpha-Thalassemia Major Presenting in a Term Neonate without Hydrops. Pediatric and Developmental Pathology, 2005, 8, 706-709.	1.0	9
258	A DNA Enzyme Against Plasminogen Activator Inhibitor- type 1 (PAI-1) Limits Neointima Formation After Angioplasty in an Obese Diabetic Rodent Model. Journal of Cardiovascular Pharmacology, 2007, 50, 633-640.	1.9	9
259	Monomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disorders. Leukemia and Lymphoma, 2010, 51, 1761-1764.	1.3	9
260	Transient Celiac Autoimmunity in an Adult. Journal of Clinical Gastroenterology, 2011, 45, 912-913.	2.2	9
261	Lymphoid follicle colonization by Bcl-2bright+CD10+ B-cells ("follicular lymphoma in situâ€) at nodal and extranodal sites can be a manifestation of follicular homing of lymphoma. Human Pathology, 2013, 44, 1328-1340.	2.0	9
262	<i>MLL</i> / <i>KMT2A</i> translocations in diffuse large Bâ€cell lymphomas. Hematological Oncology, 2015, 33, 239-246.	1.7	9
263	Fatal Streptococcus pneumoniae Sepsis in a Patient With Celiac Disease-Associated Hyposplenism. ACG Case Reports Journal, 2016, 3, e140.	0.4	9
264	Perioperative Immunomodulation With Flt3 Kinase Ligand or a Whole Tumor Cell Vaccine Is Associated With a Reduction in Lung Metastasis Formation After Laparotomy in Mice. Surgical Innovation, 2006, 13, 41-47.	0.9	8
265	Analysis of dendritic cells and ischemia-reperfusion changes in postimplantation renal allograft biopsies may serve as predictors of subsequent rejection episodes. Kidney International, 2018, 93, 1227-1239.	5.2	8
266	Comparison of several author indices for gauging academic productivity. Informatics in Medicine Unlocked, 2019, 15, 100166.	3.4	8
267	EBV-associated, extranodal NK-cell lymphoma, nasal type of the breast, after heart transplantation. Modern Pathology, 2004, 17, 125-130.	5.5	8
268	Coeliac disease and the videocapsule: what have we learned till now. Annals of Translational Medicine, 2017, 5, 197-197.	1.7	8
269	SNP-Arrays Provide New Insights Into the Pathogenesis of Post-Transplant Diffuse Large B-Cell Lymphoma (PT-DLBCL) Blood, 2009, 114, 444-444.	1.4	8
270	The spectrum of myelodysplastic syndromes post-solid organ transplantation: A single institutional experience. Leukemia Research, 2007, 31, 59-65.	0.8	7

#	Article	IF	CITATIONS
271	Methods to quantitate videocapsule endoscopy images in celiac disease. Bio-Medical Materials and Engineering, 2014, 24, 1895-1911.	0.6	7
272	Practical diagnostic approaches to composite plasma cell neoplasm and low grade Bâ \in cell lymphoma/clonal infiltrates in the bone marrow. Hematological Oncology, 2015, 33, 31-41.	1.7	7
273	Use of shape-from-shading to characterize mucosal topography in celiac disease videocapsule images. World Journal of Gastrointestinal Endoscopy, 2017, 9, 310.	1.2	7
274	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer Journal, 2022, 12, 25.	6.2	7
275	T-Cell lymphoblastic lymphoma presenting as bilateral multinodular breast masses: A case report and review of the literature. American Journal of Hematology, 2005, 80, 216-222.	4.1	6
276	Primary Burkitt lymphoma of the uterine corpus. Leukemia and Lymphoma, 2006, 47, 141-145.	1.3	6
277	Hemolysis Interferes with the Detection of Anti–Tissue Transglutaminase Antibodies in Celiac Disease. Clinical Chemistry, 2010, 56, 1034-1036.	3.2	6
278	Tâ€cell acute lymphoblastic leukaemia after liver transplantation: postâ€transplant lymphoproliferative disorder or coincidental <i>de novo</i> leukaemia?. Hematological Oncology, 2013, 31, 49-53.	1.7	6
279	Gains of <i><scp>CCND</scp>3</i> gene in ocular adnexal <scp>MALT</scp> lymphomas: an integrated analysis. British Journal of Haematology, 2013, 160, 719-722.	2.5	6
280	Haploinsufficiency of Bcl11b suppresses the progression of ATM-deficient T cell lymphomas. Journal of Hematology and Oncology, 2015, 8, 94.	17.0	6
281	Trends in celiac disease research. Computers in Biology and Medicine, 2015, 65, 369-378.	7.0	6
282	Cytogenetic analysis of adult T-Cell leukemia/lymphoma: evaluation of a Caribbean cohort. Leukemia and Lymphoma, 2019, 60, 1598-1600.	1.3	6
283	Refractory celiac disease type II: An atypical case highlighting limitations of the current classification system. Hematological Oncology, 2020, 38, 399-405.	1.7	6
284	Cellular and molecular bases of refractory celiac disease. International Review of Cell and Molecular Biology, 2021, 358, 207-240.	3.2	6
285	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. Oncolmmunology, 2021, 10, 1928365.	4.6	6
286	Spindle-cell (Sarcomatoid) Variant of Cutaneous Anaplastic Large-cell Lymphoma (C-ALCL). American Journal of Surgical Pathology, 2021, 45, 796-802.	3.7	6
287	Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood, 2021, 138, 165-165.	1.4	6
288	Development of hairy cell leukemia in a patient after cardiac transplantation. Leukemia and Lymphoma, 2006, 47, 361-363.	1.3	5

#	Article	IF	CITATIONS
289	Hematogones are markedly decreased in chronic myeloid leukemia: multiparametric flow cytometric analysis. Leukemia and Lymphoma, 2011, 52, 680-686.	1.3	5
290	An update on the management of peripheral T-cell lymphoma and emerging treatment options. Journal of Blood Medicine, 2011, 2, 119.	1.7	5
291	Lethal T- and NK-cell lymphomas mimicking granulomatous panniculitidies: a clinicopathologic study of three cases. Journal of Cutaneous Pathology, 2011, 38, 483-491.	1.3	5
292	CD19-negative B-lymphoblastic leukemia associated with hypercalcemia, lytic bone lesions and aleukemic presentation. Leukemia and Lymphoma, 2015, 56, 1533-1537.	1.3	5
293	Primary large Bâ€cell lymphoma of the central nervous system with cyclin $\langle scp \rangle D1 \langle scp \rangle$ expression and t(11;14) ($\langle i \rangle IGHâ \in \langle i \rangle \langle scp \rangle CCND1 \langle scp \rangle \rangle \langle i \rangle$: Diffuse large Bâ cell lymphoma with $\langle i \rangle \langle scp \rangle CCND1 \langle scp \rangle \langle i \rangle$ rearrangement or mantle cell lymphoma?. Hematological Oncology, 2020, 38, 817-822.	1.7	5
294	Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients. Journal of Cutaneous Pathology, 2021, 48, 1367-1378.	1.3	5
295	The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma). Blood, 2014, 124, 4449-4449.	1.4	5
296	RNA Sequencing of Primary Cutaneous and Breast-Implant Associated Anaplastic Large Cell Lymphomas Reveals Infrequent Fusion Transcripts and Upregulation of PI3K/AKT Signaling via Neurotrophin Pathway Genes. Cancers, 2021, 13, 6174.	3.7	5
297	An Unusual Finding in the Renal Medulla. American Journal of Kidney Diseases, 2005, 46, 780-786.	1.9	4
298	Response to Letter from Altman and Bécart. Immunity, 2009, 31, 2-3.	14.3	4
299	Diffuse large B-cell lymphoma with TEL/ETV6 translocation. Human Pathology, 2009, 40, 588-593.	2.0	4
300	Follicular lymphoma (inÂsitu) pattern in the bone marrow: does it indicate an early stage in disease evolution?. Clinical Case Reports (discontinued), 2015, 3, 442-443.	0.5	4
301	Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. Blood, 2019, 134, 19-19.	1.4	4
302	Cystosarcoma Phyllodes of the Breast Occurring in a Child With Subsequent Diagnosis of Celiac Disease. Journal of Pediatric Gastroenterology and Nutrition, 2003, 36, 644-646.	1.8	3
303	A Signaling Pathway Mediating Downregulation of BCL6 in Germinal Center B Cells Is Blocked by BCL6 Gene Alterations in B Cell Lymphoma. Cancer Cell, 2007, 12, 403.	16.8	3
304	Overexpression of Interleukin-1β Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-Derived Suppressor Cells in Mice. Cancer Cell, 2008, 14, 494.	16.8	3
305	Trends in gluten research and its relationship to autoimmune and allergic diseases. Informatics in Medicine Unlocked, 2016, 3, 7-14.	3.4	3
306	Cyclin D1–negative mantle cell lymphoma with aberrant CD3 expression. Blood, 2017, 130, 1388-1388.	1.4	3

#	Article	IF	CITATIONS
307	Research publication trends regarding the extraintestinal manifestations of celiac disease. Informatics in Medicine Unlocked, 2019, 17, 100242.	3.4	3
308	The clinical and pathological features of plasma cell myeloma post solid organ transplantation. American Journal of Hematology, 2020, 95, 1531-1541.	4.1	3
309	Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype. Blood, 2019, 134, 2909-2909.	1.4	3
310	Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse Large B-Cell Lymphoma. Blood, 2008, 112, 801-801.	1.4	3
311	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2011, 118, 949-949.	1.4	3
312	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 641-641.	1.4	3
313	Activating Mutations In Fyn Kinase In Peripheral T-Cell Lymphomas. Blood, 2013, 122, 811-811.	1.4	3
314	Genetic Mechanisms of Immune Escape in Diffuse Large B Cell Lymphoma. Blood, 2014, 124, 1692-1692.	1.4	3
315	Role and Mechanisms of Rhoa G17V in the Pathogenesis of AITL. Blood, 2016, 128, 608-608.	1.4	3
316	Synergistic Combinations of Histone Deacetylase Inhibitors and Decitabine Induce a Unique Gene Expression and Epigenetic Profile In Models of Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 435-435.	1.4	3
317	Masson Trichrome and Sulfated Alcian Blue Stains Distinguish Light Chain Deposition Disease From Amyloidosis in the Lung. American Journal of Surgical Pathology, 2021, 45, 405-413.	3.7	3
318	Pathology Quiz Case 2. JAMA Otolaryngology, 2009, 135, 320.	1.2	2
319	Nodular pattern of bone marrow infiltration: frequent finding in immunosuppression-related EBV-associated large B-cell lymphomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 323-336.	2.8	2
320	Peripheral T-cell lymphoma emerging in a patient with aggressive polymyositis: molecular evidence for neoplastic transformation of an oligoclonal T-cell infiltrate. Acta Neuropathologica, 2013, 126, 595-601.	7.7	2
321	Color masking improves classification of celiac disease in videocapsule endoscopy images. Computers in Biology and Medicine, 2019, 106, 150-156.	7.0	2
322	A peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder: efficacy of pralatrexate in primary refractory disease and review of the literature. Leukemia and Lymphoma, 2019, 60, 3300-3303.	1.3	2
323	Role of Rhoa G17V in Cell Migration and Transformation in Angioimmunoblastic T-Cell Lymphoma. Blood, 2018, 132, 4122-4122.	1.4	2
324	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. Blood, 2018, 132, 922-922.	1.4	2

#	Article	IF	CITATIONS
325	Potential Role Of RUNX1 In The Pathogenesis Of Juvenile Myelomonocytic Leukemia (JMML). Blood, 2013, 122, 45-45.	1.4	2
326	Mutational Loss of PTEN Induces Resistance to NOTCH1 Inhibition in T-ALL Blood, 2007, 110, 5-5.	1.4	2
327	BRAF V600E Mutation Appears Specific for Hairy Cell Leukemia Among Low and Intermediate Grade B-Cell Lymphomas: Utility of a Real Time PCR Based Approach for Detection. Blood, 2011, 118, 2635-2635.	1.4	2
328	Overexpression of Interleukin- $1^{\hat{1}^2}$ Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-Derived Suppressor Cells in Mice. Cancer Cell, 2011, 19, 154.	16.8	1
329	Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S216.	0.4	1
330	Postâ€ŧransplant lymphoproliferative disorder: a heterogeneous conundrum – response to Weisenburger <scp>DD</scp> & Gross <scp>TG</scp> . British Journal of Haematology, 2017, 179, 856-857.	2.5	1
331	T-Cell Lymphomas. , 2018, , 1343-1380.		1
332	TARGETING THE PERIPHERAL T-CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5-AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL-MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY. Hematological Oncology, 2019, 37, 178-179.	1.7	1
333	Posttransplant lymphoproliferative disorder: EBVâ^' plasma cell myeloma with large multinucleated plasma cells. Blood, 2019, 134, 992-992.	1.4	1
334	Cancer testis antigen expression across Tâ€cell lymphoma subtypes. Hematological Oncology, 2020, 38, 827-830.	1.7	1
335	MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. Blood, 2019, 134, 5092-5092.	1.4	1
336	Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas. Blood, 2008, 112, 622-622.	1.4	1
337	In Vivo Functional Dissection of the Chromosome 13q14 Tumor Suppressor Locus Reveals That Extent of Deletions Impacts Disease Course and Phenotype. Blood, 2011, 118, 468-468.	1.4	1
338	Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate Blood, 2012, 120, 2758-2758.	1.4	1
339	Leukemogenic Transformation of Hematopoietic Cells by Constitutive Activation of Canonical Wnt Signaling in Osteoblast Precursors. Blood, 2012, 120, 509-509.	1.4	1
340	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 544-544.	1.4	1
341	Recurrent Rhoa Mutations In Peripheral T-Cell Lymphoma. Blood, 2013, 122, 846-846.	1.4	1
342	STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 365-365.	1.4	1

#	Article	IF	CITATIONS
343	Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2014, 124, 143-143.	1.4	1
344	Targeting the Osteoblast in Myelodysplasia and Acute Myeloid Leukemia. Blood, 2015, 126, 2551-2551.	1.4	1
345	VAV1 Activating Mutations and Translocations in Peripheral T-Cell Lymphomas. Blood, 2016, 128, 2741-2741.	1.4	1
346	Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning. Blood, 2019, 134, 2891-2891.	1.4	1
347	Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 1499-1499.	1.4	1
348	Henoch-Schönlein Purpura Associated With Diffuse Large B-cell Lymphoma of the Orbit. Ophthalmic Plastic and Reconstructive Surgery, 2021, 37, e47-e50.	0.8	1
349	Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms. Blood, 2021, 138, 2395-2395.	1.4	1
350	ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis. Blood, 2021, 138, 2403-2403.	1.4	1
351	Notable Patterns in the Genomic Landscape of Adult T-Cell Leukemia/Lymphoma Encountered in HTLV-1 Endemic Western World Regions. Blood, 2021, 138, 810-810.	1.4	1
352	Indolent T- and NK-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract: Current Understanding and Outstanding Questions. Hemato, 2022, 3, 219-231.	0.6	1
353	Refractory celiac disease (RCD): Histology, T-cell clonality and clinical course. Gastroenterology, 2000, 118, A364.	1.3	0
354	Hepatitis C — related granulomas occurring post orthotopic liver transplants (OLTX) are associated with poor clinical outcomes. Journal of Hepatology, 2002, 36, 188.	3.7	0
355	Alpha B-crystallin (aB-C) expression in neoplastic and non neoplastichepato-biliary disease: an immunohistochemical study. Journal of Hepatology, 2002, 36, 268.	3.7	0
356	Regression of a localized gastric amyloid mass in a patient treated for multiple myeloma. Gastrointestinal Endoscopy, 2009, 69, 950-951.	1.0	0
357	Is There Any Value in Performing Duodenal Bulb Biopsies for Diagnosing Celiac Disease?. Gastrointestinal Endoscopy, 2009, 69, AB204.	1.0	0
358	57 High-resolution genomic profiling of 533 B-cell lymphomas defines distinct tumor signatures, genomic aberrations correlated with outcome and pathogenetic subgroups. European Journal of Cancer, Supplement, 2010, 8, 26.	2.2	0
359	T lymphoblastic leukemia/lymphoma and human immunodeficiency virus infection. Journal of Hematopathology, 2011, 4, 233-235.	0.4	0
360	Transient Celiac Autoimmunity or Just Temporary Fluctuation?. Journal of Clinical Gastroenterology, 2012, 46, 434.	2.2	0

#	Article	IF	CITATIONS
361	Phenotypic and Genotypic Profiling of MDM2, Respective to the TP53 Genetic Status, in Diffuse Large B-cell Lymphoma Patients Treated With Rituximab-CHOP Immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S146-S147.	0.4	0
362	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in de novo Diffuse Large B-Cell Lymphoma in Western Countries: A report from The International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S144-S145.	0.4	0
363	Genomeâ€wide <scp>DNA</scp> profiling identifies clonal heterogeneity in marginal zone lymphomas. British Journal of Haematology, 2014, 164, 896-899.	2.5	0
364	Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S220-S221.	0.4	0
365	Clinical and Biological significance of MYC/BCL6 dual gene rearrangements and protein co-expression in de novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S228.	0.4	0
366	MYC Signatures and Characterization of MYC-Driven Aggressive B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S223.	0.4	0
367	Nuclear coexpression of NF-ήB subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium. Clinical Lymphoma, Myeloma and Leukemia, 2015. 15. S224.	0.4	0
368	B-cell lymphoma with pseudopapillary features, myxoid changes and lack of CD20 expression: a diagnostic pitfall. Leukemia and Lymphoma, 2015, 56, 3213-3215.	1.3	0
369	ETS1 PHOSPHORYLATION AT THR38 (PETS1) IS ASSOCIATED WITH CELL OF ORIGIN (COO), CELL CYCLE ACTIVATION, AND INFERIOR OUTCOME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). Hematological Oncology, 2017, 35, 153-154.	1.7	0
370	The ZFX Target Gene, FAM92A1, Is a Marker of AML Aggressiveness. American Journal of Clinical Pathology, 2017, 147, S179-S180.	0.7	0
371	SURG-20. CRANIOTOMY AND SURVIVAL FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Neuro-Oncology, 2017, 19, vi239-vi239.	1.2	0
372	MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. Hematological Oncology, 2019, 37, 181-182.	1.7	0
373	EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV-SPECIFIC CTL AND IBRUTINIB THERAPY. Hematological Oncology, 2019, 37, 130-132.	1.7	0
374	Cystic Lung: Manifestation of Light Chain Deposition Disease. , 2019, , .		0
375	Interphase fluorescence in situ hybridization analysis of CD19â€selected cells: Utility in detecting disease in postâ€therapy samples of Bâ€cell neoplasms. Cancer Medicine, 2021, 10, 2680-2689.	2.8	0
376	Protein Signature of LMP1 Signaling in PTLDs Identifies and Mimics Inter/Perifollicular CD30+ EBVâ^' B Blasts Blood, 2004, 104, 3251-3251.	1.4	0
377	Presentation of Celiac Disease and Biopsy Findings. American Journal of Gastroenterology, 2006, 101, S147-S148.	0.4	0
378	Differential Gene Expression in Nodular Sclerosis Hodgkin Lymphoma: The Role of the Reactive Infiltrate in Disease Pathogenesis Blood, 2006, 108, 2264-2264.	1.4	0

#	Article	IF	CITATIONS
379	Collagenous and Lymphocytic Colitis in Celiac Disease: Evaluation of Standardized Morbidity Ratios. American Journal of Gastroenterology, 2007, 102, S434.	0.4	Ο
380	Gene Expression Analysis of B-Cell Post Transplant Lymphoproliferative Disorders Provides Insights into Disease Biology Blood, 2007, 110, 3172-3172.	1.4	0
381	Mutually Exclusive Structural Alterations of BLIMP1 and BCL6 Contribute to the Pathogenesis of Activated B Cell Type Diffuse Large B Cell Lymphoma Blood, 2009, 114, 445-445.	1.4	0
382	microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. Journal of Cell Biology, 2010, 188, i12-i12.	5.2	0
383	T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant Journal of Clinical Oncology, 2010, 28, 8056-8056.	1.6	0
384	BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL). Blood, 2011, 118, 2634-2634.	1.4	0
385	Deregulated Expression of HDAC9 in B-Cells Leads to Lymphoproliferative Disorders As Well As Germinal Center and Post-Germinal Center Derived Lymphomas. Blood, 2012, 120, 3505-3505.	1.4	0
386	IL10 Receptor a Is a Novel Therapeutic Target That Is Epigenetically Disregulated in Low Grade Lymphomas with Plasmacytic Differentiation Blood, 2012, 120, 2383-2383.	1.4	0
387	Dasatinib Therapy Affects Bone Homeostasis in Patients with Chronic Myelogenous Leukemia in Chronic Phase Independently of Molecular Response. Blood, 2012, 120, 1682-1682.	1.4	0
388	Novel Genomic Alterations in MCL1 and ARID1A Identified in Pediatric Burkitt Lymphoma Using Targeted High-Throughput Sequencing. Blood, 2012, 120, 899-899.	1.4	0
389	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. Blood, 2013, 122, 77-77.	1.4	0
390	MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 363-363.	1.4	0
391	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 213-213.	1.4	0
392	Next-Generation High Throughput Sequencing Analysis In The Search Of Infectious Pathogens In Suspect Lymphoproliferations. Blood, 2013, 122, 3019-3019.	1.4	0
393	Genomic and Targeted Mutational Analysis of T/NK-Cell Post-Transplant Lymphoproliferative Disorders Provides Insight into Disease Biology. Blood, 2015, 126, 1475-1475.	1.4	0
394	Abstract 2714: Analytical validation of clinical whole genome and transcriptome sequencing of patient derived tumors: clinical application of whole genome sequencing for reporting targetable variants in cancer. , 2017, , .		0
395	Constitutive Phosphorylation of CYLD Promotes ATLL Survival By Inhibiting RIPK1-Dependent Cell Death. Blood, 2018, 132, 1581-1581.	1.4	0
396	Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis. Blood, 2019, 134, 3486-3486.	1.4	0

#	Article	IF	CITATIONS
397	A survey of cancer testis antigen (CTA) expression across T-cell lymphoma subtypes Journal of Clinical Oncology, 2020, 38, e15246-e15246.	1.6	0
398	Abstract 171: Genomic and phenotypic analysis of post-transplant plasmablastic lymphomas. , 2020, , .		0
399	Genomic and Transcriptional Characterization of Primary Mediastinal Large B Cell Lymphoma. Blood, 2021, 138, 2398-2398.	1.4	0